TGFB1 and Miyoshi myopathy: In contrast, in agreement with our results, Hadjiaggelidou et al. demonstrated, in a small population of MM patients, a reduction in TGF-β levels in the Lenalidomide plus Dexamethasone treatment group versus those patients treated with Dexamethasone plus Bortezomib [20].